QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial
CVE:RVV

Revive Therapeutics (RVV) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)
Free RVV Stock Alerts
C$0.08
+0.01 (+14.29%)
(As of 07/22/2019)
Compare
Today's Range
C$0.08
▼
C$0.09
50-Day Range
C$0.08
▼
C$0.08
52-Week Range
C$0.07
▼
C$0.25
Volume
212,852 shs
Average Volume
93,085 shs
Market Capitalization
C$5.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
RVV stock logo

About Revive Therapeutics Stock (CVE:RVV)

Revive Therapeutics Ltd. develops and commercializes cannabinoid-based products in Canada. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial. The company has a research and development supply and collaboration agreement with WeedMD Inc. Revive Therapeutics Ltd. was incorporated in 2012 and is headquartered in Vaughan, Canada.

RVV Stock Price History

RVV Stock News Headlines

April 18, 2024 | markets.businessinsider.com
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
March 27, 2024 | finanznachrichten.de
Revive Therapeutics Ltd.: Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
April 19, 2024 | Crypto 101 Media (Ad)
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
March 27, 2024 | finance.yahoo.com
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
March 19, 2024 | finanznachrichten.de
Revive Therapeutics Ltd.: Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
March 19, 2024 | markets.businessinsider.com
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
March 12, 2024 | finanznachrichten.de
Revive Therapeutics Ltd.: Revive Therapeutics Provides Corporate Update
March 12, 2024 | financialpost.com
Revive Therapeutics Provides Corporate Update
April 19, 2024 | Crypto 101 Media (Ad)
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
February 26, 2024 | markets.businessinsider.com
Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110
February 1, 2024 | markets.businessinsider.com
Revive Therapeutics Explores the Use of Bucillamine for Long COVID
January 31, 2024 | markets.businessinsider.com
Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500
January 24, 2024 | financialpost.com
Revive Therapeutics Ltd. Announces Offering of Up to $3 Million
January 16, 2024 | tmcnet.com
Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada
January 10, 2024 | finanznachrichten.de
Revive Therapeutics Ltd.: Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
January 10, 2024 | markets.businessinsider.com
Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
January 8, 2024 | msn.com
Travere Therapeutics expects Q4 net product sales from continuing operations to be about $40M
December 20, 2023 | markets.businessinsider.com
Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
December 18, 2023 | markets.businessinsider.com
Revive Therapeutics To Work With Attwill For Development Of Lyophilized Formulation Of Bucillamine
December 18, 2023 | financialpost.com
Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine
October 17, 2023 | markets.businessinsider.com
Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure
October 17, 2023 | markets.businessinsider.com
Revive Therapeutics Agrees With DRDC To Evaluate Bucillamine For Nerve Agent Exposure
October 11, 2023 | finanznachrichten.de
Revive Therapeutics Ltd.: Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
October 11, 2023 | tmcnet.com
Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
September 28, 2023 | ft.com
Italy turns to Kyrgyz shepherds to revive Sardinian farming
August 22, 2023 | finanznachrichten.de
Revive Therapeutics Ltd.: Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development
August 22, 2023 | stockhouse.com
Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development
See More Headlines
Receive RVV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revive Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/19/2024
Next Earnings (Estimated)
6/04/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
CVE
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
CVE:RVV
CUSIP
N/A
CIK
N/A
Web
www.revivethera.com
Phone
+1-905-6055535
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.14
Quick Ratio
6.03

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
C$0.03 per share
Price / Cash Flow
3.18
Book Value
C$0.02 per share
Price / Book
4.21

Miscellaneous

Outstanding Shares
72,411,000
Free Float
N/A
Market Cap
C$5.79 million
Optionable
Not Optionable
Beta
N/A
5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Craig Leon (Age 51)
    Chairman & CEO
  • Mr. Fabio Chianelli (Age 41)
    Pres & Director
  • Mr. Carmelo Marrelli C.A. (Age 48)
    C.P.A., CPA, B.Comm., CA, CGA, ACIS, Chief Financial Officer

Key Competitors

View All Competitors

Insiders


RVV Stock Analysis - Frequently Asked Questions

How have RVV shares performed in 2024?

Revive Therapeutics' stock was trading at C$0.08 at the start of the year. Since then, RVV stock has increased by 0.0% and is now trading at C$0.08.
View the best growth stocks for 2024 here.

When is Revive Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 4th 2024.
View our RVV earnings forecast.

What other stocks do shareholders of Revive Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revive Therapeutics investors own include Heat Biologics (HTBX), Green Organic Dutchman (TGOD), Aurora Cannabis (ACB), CytoDyn (CYDY), Genprex (GNPX), iBio (IBIO), Sorrento Therapeutics (SRNE), Workhorse Group (WKHS), Acasti Pharma (ACST) and Anavex Life Sciences (AVXL).

How do I buy shares of Revive Therapeutics?

Shares of RVV stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (CVE:RVV) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
SHOCKING Crypto Leak…
Crypto 101 Media
My biggest AI fear
Paradigm Press